



NORWAY

(19) NO

(51) Int Cl.

A61K 48/00 (2006.01) *A61P 9/10 (2006.01)*
A61K 9/00 (2006.01) *C07K 2/00 (2006.01)*
A61K 9/127 (2006.01) *C07K 14/47 (2006.01)*
A61K 9/14 (2006.01) *C12N 9/88 (2006.01)*
A61K 9/16 (2006.01) *C12N 15/00 (2006.01)*
A61K 31/7088 (2006.01) *C12N 15/117 (2010.01)*
A61K 31/7105 (2006.01) *C12N 15/85 (2006.01)*
A61K 31/7115 (2006.01) *C12N 15/88 (2006.01)*
A61P 3/00 (2006.01) *C12P 21/00 (2006.01)*
A61P 3/10 (2006.01)

Norwegian Industrial Property Office

- (45) Translation Published 2022.05.30
- (80) Date of The European Patent Office Publication of the Granted Patent 2022.03.02
- (86) European Application Nr. 12858350.7
- (86) European Filing Date 2012.12.14
- (87) The European Application's Publication Date 2014.10.22
- (30) Priority 2011.12.16, US, 201161576705 P
2012.04.02, US, 201261618957 P
2012.05.17, US, 201261648244 P
2012.08.10, US, 201261681712 P
2012.09.04, US, 201261696381 P
2012.10.03, US, 201261709303 P
2012.10.11, US, 201261712490 P
2012.10.03, WO, PCT/US12/058519
- (84) Designated Contracting States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
- (73) Proprietor ModernaTX, Inc., 200 Technology Square, Cambridge, MA 02139, USA
- (72) Inventor DE FOUGEROLLES, Antonin, 15, avenue Neptune, B-1410 Waterloo, Belgia
WOOD, Kristy M., 501 Huron Avenue Unit 2, Cambridge, Massachusetts 02138, USA
ELBASHIR, Sayda M., 149 Grove Street, Cambridge, Massachusetts 02138, USA
AFEYAN, Noubar B., 1 Memorial Drive 7th Floor, Cambridge, Massachusetts 02142, USA
VALENCIA, Pedro, 60 Wadsworth Street Apt. 5G, Cambridge, Massachusetts 02142, USA
SCHRUM, Jason P., 20 Watertown ST Unit 129, Watertown MA 02472-2580, USA
- (74) Agent or Attorney Budde Schou A/S, Dronningens Tværgade 30, 1302 KØBENHAVN K, Danmark
-
- (54) Title **MODIFIED MRNA COMPOSITIONS**

(56) References

Cited:

WO-A2-2012/135805

US-A1- 2009 264 511

US-A1- 2010 015 232

WO-A2-2013/151736

US-A1- 2002 130 430

US-A1- 2008 274 463

US-A1- 2009 286 852

US-A1- 2011 244 026

WO-A1-2011/068810

WO-A2-2009/051451

US-A1- 2002 064 517

WO-A1-2013/039857

WO-A2-2011/130624

WO-A2-2013/039861

US-A1- 2006 018 971

US-B1- 6 303 378

NORBERT PARDI ET AL: "Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes", JOURNAL OF CONTROLLED RELEASE., vol. 217, November 2015 (2015-11), pages 345-351, XP055231069, NL ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2015.08.007

BASHA ET AL.: 'Influence of Cationic lipid Composition on Gene Silencing Properties of Lipid Nanoparticle Formulations of siRNA in Antigen-Presenting Cells.' MOLECULAR THERAPY. vol. 19, no. 12, October 2011, pages 2186 - 2200, XP055024764

OLIWIA ANDRIES ET AL: "N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice", JOURNAL OF CONTROLLED RELEASE., vol. 217, November 2015 (2015-11), pages 337-344, XP055231071, NL ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2015.08.051

SEMPLE ET AL.: 'Rational design of cationic lipids for siRNA delivery.' NATURE BIOTECHNOLOGY vol. 28, no. 2, February 2010, pages 172 - 176+2PP, XP002633693

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Farmasøytisk sammensetning omfattende et 1-metyl-pseudouridin-modifisert mRNA som koder for et polypeptid av interesse, hvori mRNA-et formuleres som en lipidnanopartikkel.
2. Den farmasøytiske sammensetningen ifølge krav 1, hvori mRNA-et koder for et immunogent peptid eller polypeptid.
3. Den farmasøytiske sammensetningen ifølge et hvilket som helst av kravene 1 eller 2 for anvendelse i en fremgangsmåte for behandling eller forebygging av en sykdom eller tilstand hos et menneske eller i et annet pattedyr.
4. Den farmasøytiske sammensetningen for anvendelse ifølge krav 3, hvori mRNA-et koder for et immunogent peptid eller polypeptid og anvendes for å fremkalle eller fremprovosere en immunrespons.
5. Den farmasøytiske sammensetningen ifølge krav 1 eller 2 eller den farmasøytiske sammensetningen for anvendelse ifølge krav 3 eller 4, hvori mRNA-et koder en polypeptidsekvens for en vaksine.
6. Den farmasøytiske sammensetningen for anvendelse ifølge et hvilket som helst av kravene 3–5, hvori sammensetningen administreres via en intravenøs, intramuskulær eller subkutan vei.